



20th KM Hosur Road, Electronics City, Bangalore 560 100

For Immediate Release

Bangalore, 15 July 2014

**Biocon's Q1 FY 2015 Results Conference Call**

**At 12:30 pm IST on 25 July 2014**

The management team of Biocon Limited will organize a **conference call for analysts and investors on Friday, 25 July 2014 at 12:30 pm IST** following the announcement of financial results for the quarter ended 30 June 2014, on Thursday, 24 July 2014.

The call will be initiated with a brief management discussion on the Q1 FY 2015 performance followed by an interactive Question & Answer session. Ms. Kiran Mazumdar-Shaw, Chairperson & Managing Director, Biocon Limited, and other members of the senior management team will represent Biocon on the conference call.

Details of the conference call are as under:

<b>Date:</b>	Friday, 25 July 2014
<b>Time:</b>	12:30 pm IST
<b>Dial-in Numbers:</b>	
Primary Number	+91 22 3938 1081
Secondary Number	+91 22 6746 5891
Local Access Number	6000 1221 (Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada. Accessible from all major carriers except BSNL/MTNL.)  3940 3977 (Available in - Ahmedabad, Bangalore, Chandigarh, Chennai, Gurgaon (NCR), Hyderabad, Kochi/Cochin, Kolkata, Lucknow, Pune. Accessible from all carriers)
USA Toll Free	1 866 746 2133
UK Toll Free	0 808 101 1573
Singapore Toll Free	800 101 2045
HK Toll Free	800 964 448
<b>Pre-Registration Facility</b> (Special Facility where you can pre-register for the call, and then directly dial-in on the day of the call, without waiting for the operator. You will also get reminders to attend the investor call.)	<ul style="list-style-type: none"><li>• Step 1: Pre-register <a href="#">here</a>; You will receive a passcode and a pin for the call on the registered email address</li><li>• Step 2: Dial into the call on the Conference Call date, enter the passcode &amp; pin as prompted</li><li>• Step 3: You are directly connected to the call</li></ul>

**Replay Facility**

Dial in number : +91 22 6181 3322

Playback ID : 311121

The replay facility will begin after the conference call ends.

Replay available till 02 August 2014.

The transcript of the conference call will be available within 7 working days of the call on the corporate website: [www.biocon.com](http://www.biocon.com)

**About Biocon**

Established in 1978, Biocon Limited, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. Biocon's robust product portfolio includes the world's first Pichia-based recombinant human Insulin (INSUGEN®), Glargine (BASALOG®), as well as MABs like BioMAB-EGFR® for head & neck cancer and Alzumab™ for Psoriasis. It has now successfully developed the world's most affordable Trastuzumab, CANMAB™ for HER2 positive breast cancer introduced in India in 2014. [www.biocon.com](http://www.biocon.com)

**For further information please contact:**

Saurabh Paliwal / Sweta Pachlangiya

Biocon Limited

Tel: +91 80 2808 2040 / 5481

Fax: +91 80 2852 3423

Email: [saurabh.paliwal@biocon.com](mailto:saurabh.paliwal@biocon.com) /[sweta.pachlangiya@syngeneintl.com](mailto:sweta.pachlangiya@syngeneintl.com)

Diwakar Pingle

Christensen Investor Relations

Tel: +91 22 4215 0210

Email: [dpingle@ChristensenIR.com](mailto:dpingle@ChristensenIR.com)

**Disclaimer:** Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. There can be no assurance that future developments affecting Biocon and its subsidiaries / associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Biocon does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.